Boralex

Phase A — Understand the business

Lens 1 · Company Overview

Boralex is a pure-play renewable independent power producer (IPP) — it develops, builds, owns and operates wind, solar, hydro and battery-storage (BESS) assets and sells the output under long-term contracts. Founded 1990 (grew out of Québec packaging group Cascades' energy arm), HQ Kingsey Falls / Montréal, Québec; ~35-year operating history.

Scale (as of 2025-12-31 / Q1-2026): total installed capacity 3,783 MW, +>50% over five years. By source:

• Wind 2,952 MW (78%) — the core; Boralex is the largest independent onshore-wind producer in France
• Storage (BESS) 385 MW (10%)
• Solar 268 MW (7%)
• Hydro 178 MW (5%)

How it makes money: long-term Power Purchase Agreements (PPAs), government feed-in tariffs / CfDs, and corporate PPAs (cPPAs). Revenue is ~contracted and inflation-linked, so the P&L behaves like a levered utility/infrastructure annuity, not a merchant generator. Weighted-average remaining contract life ~11 years (2024), targeted to 14 years by 2030. Corporate cPPA counterparties named: Orange, IBM, Auchan, Metro France, Saint-Gobain.

Contract structure / payment terms: blend of (a) 15–20yr utility PPAs & feed-in tariffs (the annuity), (b) CfDs from competitive tenders (France/UK), (c) short-term "18-month merchant window" that newly-commissioned French wind farms sell into at market before their long-term PPA starts (a deliberate, transitional merchant exposure), and (d) cPPAs. Not take-or-pay commodity supply; the concentration risk is regulatory/price-regime, not single-customer.

Lens 2 · Supply Chain

Upstream inputs → Boralex → offtaker, with named links:

• Turbine / equipment OEMs (upstream, not disclosed by name in the material read — European onshore wind is served by Vestas, Siemens Gamesa, Nordex; ****). This is the CapEx-cost chokepoint: turbine price inflation + interest rates drove the sector's 2022–24 de-rate (Lens 8).
• BESS suppliers — battery packs for the 385 MW storage fleet + Oxford BESS (125 MW / 500 MWh) and Tilbury (300 MW) pipeline; supplier not named ``. Battery cell supply (largely China-linked LFP) is a genuine cost/lead-time chokepoint for the storage build-out.
• EPC / construction — Boralex self-develops and manages construction; Oxford BESS financed with a C$202M package (C$166M construction loan + C$25M bridge + C$11M LC).
• Capital providers (the real "supply chain" for an IPP) — project-level lenders fund 85% of debt (C$3.74B of C$4.4B is non-recourse project finance); corporate lenders 15% (C$646M). Equity partner Energy Infrastructure Partners (EIP) owns 30% of the French assets (bought 2021 for €532M, implying ~16× 2022 EBITDA) — a structural JV that shows up as the "joint venture contribution" line that swung EBITDA in Q1-2026.
• Grid operators / offtakers (downstream): French TSO/DSO (RTE/Enedis) + EDF as historical feed-in buyer; Canadian provincial utilities (Hydro-Québec, IESO Ontario); UK (National Grid); US (NYISO — New York State solar). Named offtakers/cPPA buyers: Orange, IBM, Auchan, Metro, Saint-Gobain.

Chokepoints: (1) turbine + battery equipment cost/lead-time; (2) grid interconnection queues; (3) permitting (esp. French onshore wind, historically litigious — see Lens 10 Innovent); (4) cost of capital — an IPP is a spread business (asset IRR minus financing cost), so rates are the supply chain. Single-source dependency is not customer-side; it is regime/regulatory (French PPA-price and tender design).

Lens 3 · Competitive Advantages (moats)

• France onshore-wind incumbency — #1 independent producer; a 35-yr permitting/development track record in one of Europe's hardest onshore-wind permitting regimes is a real, if unglamorous, moat (local relationships, site control, a de-risked pipeline). This is why Innergex, Northland, and now Brookfield covet these platforms.
• Development pipeline as the asset — 8.2–8.3 GW of secured/advanced pipeline in wind/solar/BESS across Canada, US, France, UK. For an IPP, pipeline + interconnection positions = the moat; you cannot buy them off a shelf.
• Contracted cash-flow annuity — ~11-yr WACL of largely inflation-linked PPAs gives BBB-type cash-flow visibility and cheap project debt.
• Bargaining power: modest. Boralex is a price-taker into competitive tenders (CfD auctions) and a price-taker on turbines/batteries. Its edge is executional (getting projects permitted, built, financed) not pricing power. Against offtakers it holds long contracts; against suppliers and the regulator it has little leverage — which is precisely why an infrastructure owner with a lower cost of capital (Brookfield) can pay 32% over market and still see value: they refinance the equity cheaper and compound the pipeline off-balance-sheet.

Moat verdict: a good developer platform, not a structural monopoly. The moat is durable enough to be worth acquiring but not wide enough to command a premium multiple as a stand-alone small-cap in a high-rate world — hence the 33% discount to 2021 highs that opened the door to the take-private.

Lens 4 · Segments

Boralex reports by geography (France, Canada, US, UK) and by source; it does not publish clean per-segment EBITDA in the material I could read web-only, so segment-level splits below are **partial / ** and flagged where estimated. No segments.csv data exists on the shelf.

• Geography: France (the historic core — largest independent onshore-wind producer there; also the current drag, via falling short-term PPA prices), Canada (Québec/Ontario — strongest performer; wind assets carried Q1), United States (New York solar — an "expanding market"), United Kingdom (new platform — Limekiln wind was its first UK operational project, started Q1-2025; Sallachy 43 MW + a 59 MW UK wind acquisition added Q1-2026).
• Source mix (installed, 2025-12-31): Wind 78% / Storage 10% / Solar 7% / Hydro 5%.
• Trend & cause: growth is decelerating in France on price (short-term/merchant PPA prices fell, compressing EBITDA even as volumes rose) and accelerating in Canada + storage + UK on new commissioning. The strategic tilt is deliberately toward BESS and non-France geographies to reduce French merchant-price sensitivity — the exact structural weakness Brookfield can absorb.

n/a — clean segment EBITDA split not sourced web-only; would come from the MD&A the research shelf lacks (no CIK).

---

Phase B — Measure performance

Lens 5 · Earnings Result (latest print: Q1-2026, reported 2026-05-14)

Consolidated, CAD:

Combined basis (incl. JVs): Revenue C$321M (+11%), EBITDA(A) C$207M (+8%), production 2,517 GWh (+8%).

Read: Revenue +22% and production +12% on new commissioning + better European wind — but EBITDA was flat-to-down and net income attributable to shareholders went negative. The gap is the tell: lower French short-term PPA prices and lower JV contributions ate the volume growth, and higher D&A/finance costs on the growing asset base pushed the bottom line to a loss for common holders. Production came in 1% below plan (consolidated) / 4% below (combined) — a slight operational miss. Balance sheet: C$375M cash, C$645M total available liquidity at 2026-03-31; debt principal C$4.435B consolidated. Market reaction: muted — the stock is pinned to the C$37.25 arb price; fundamentals no longer move it.

Flag vs. own history: a negative net result to shareholders on +22% revenue would normally be a yellow flag (margin/cost-of-capital compression outrunning growth). In a merchant-lite IPP this is the rate-cycle bite — and it is exactly the fundamental soft spot that (a) explains the 2021→2026 de-rate and (b) is now irrelevant to the trade because the price is fixed by contract.

Lens 6 · Earnings Calls (sentiment trend)

No transcripts on the shelf; from web coverage of the last ~4 calls:

• Recurring themes: execution of the 2030 strategic plan, large-scale project commissioning (Limekiln UK, Apuiat Québec, Tilbury/Oxford BESS), contract-duration extension (11→14 yrs), and capital discipline (10–12% levered IRR floor).
• Shift over time: the tone moved from growth-story evangelism (2024–early 2025, when the 2030 plan was unveiled) to defending EBITDA against French price weakness (Q4-2025 "earnings miss," Q1-2026 flat EBITDA) — and then, post-March 2026, the narrative is entirely transaction-integration ("next phase of growth as a standalone private company").
• What they stopped saying: stand-alone per-share value-creation / buyback talk — moot under a cash take-out. Q4-2025 EPS of C$0.13 missed a ~C$0.57 consensus badly (−77% surprise), reinforcing that the fundamentals were not the reason to own it into the bid.

Lens 7 · Comps

Renewable-IPP peer set. Multiples are `` with date, or n/a. No multiple is fabricated. Note the peer group is thinning: Innergex went private (July 2025) and Boralex is going private (Q4-2026) — a sector-wide take-private wave that is itself the most important comp signal.

Takeaway: the deal strikes Boralex at an implied ~13–14× FY25 combined EBITDA ``, a premium to Northland's ~12.2× public multiple and broadly in line with the ~16× EIP paid for 30% of the French assets in 2021. For a public small-cap the market was assigning materially less (the stock sat ~33% below 2021 highs pre-bid) — the classic private-infrastructure-vs-public-equity valuation gap that Brookfield exists to arbitrage.

Lens 8 · Stock-Price Catalysts (moves >5%, last ~5 yrs)

• Early 2021 — peak. Green-energy/ESG melt-up; BLX at all-time highs ``.
• 2021 — EIP deal. Sold 30% of French assets to Energy Infrastructure Partners for €532M @ ~16× EBITDA — a positive external valuation mark.
• 2022 — Ukraine/energy-crisis bump. European power prices spiked; BLX's western-Europe weighting fueled a relative rally even as the broad renewable complex fell.
• 2022–2024 — the de-rate. Rising rates + turbine-cost inflation + supply-chain drag re-priced the whole IPP sector; BLX fell to ~33% below 2021 highs.
• Q4-2025 (reported 2026-03) — big EPS miss (C$0.13 vs ~C$0.57), yet stock "stable" — a sign the market was already anticipating corporate action / valuing assets, not EPS.
• 2026-03-25 — THE catalyst: C$37.25 cash take-private announced, +31.8% in a day.
• 2026-06-04/05 — 99.86% shareholder + final court approval; stock converges to ~C$36.98, ~0.7% below terms.

Pattern: for most of its life BLX reacted to rates and power-price regime, not to earnings beats/misses (the Q4-25 miss barely moved it). Post-March-2026 it reacts to one thing only: deal-completion probability. Any >5% move from here would signal a regulatory-approval problem or a break — otherwise it drifts up ~0.7% into close.

---

Phase C — Judge people & books

Lens 9 · Management

• CEO Patrick Decostre (since 2020-12-01). Boralex's first employee in Europe; spent ~18 yrs building the French/European platform and developed the company's first French onshore wind farm. Track record: the France #1-independent-onshore-wind position and the 3.2→3.8 GW growth are substantially his build. Deep operator, not a financial-engineer archetype — a builder who scaled a hard-to-replicate development platform.
• CFO Philippe Bonin; CLO Pascal Hurtubise; CPCO Marie-Josée Arsenault; GM North America Robin Deveaux; GM Europe Jean-Christophe Dall'Ava. Stable, long-tenured, bilingual Québec/Europe bench.
• Capital-allocation history: disciplined — a stated 10–12% levered-IRR floor, the 2021 EIP partial-sale that crystallized a 16× mark and recycled capital, and a 20–40% payout ratio to fund organic growth. The knock is that stand-alone cost of capital was too high in 2022–25 for the market to reward the growth — an external constraint more than a management error.
• Ownership / skin in the game: principal shareholder CDPQ / La Caisse ~15–17.3% (bought Cascades' Class A stake in 2017). No insider-transactions.csv on the shelf; individual insider ownership n/a.
• Red flags: none material. The governance signal is actually positive — the take-private ran a proper Special Committee, drew three independent fairness opinions (NBCM, RBC, Desjardins), and won both ISS and Glass Lewis FOR recommendations and a 99.86% vote. That is a clean, well-shopped process, not an insider low-ball — even though CDPQ (an existing holder) is on the buy-side, the independent process and near-unanimous minority vote de-risk the conflict.
• Archetype: founder-adjacent professional builder. Implication: the asset base and pipeline are real and well-run — which is why Brookfield is buying, and why break-downside (Lens 13) is cushioned by genuine asset value.

Lens 10 · Forensic Red Flags

Web-only; no filings on the shelf, so classic forensic ratios (receivables vs. revenue, SBC-adjusted non-GAAP, goodwill) are n/a from primary filings (no CIK). What the public record shows:

• Cash flow vs. earnings: discretionary cash flow (C$71M) held up far better than net income (−C$9M to shareholders) in Q1-2026 — normal for a high-D&A infrastructure IPP where GAAP earnings understate cash. Not a red flag, but it means headline EPS is a poor gauge here (the Q4 "miss" is largely non-cash/D&A + French price).
• Leverage: C$4.4B debt, 85% non-recourse project-level — a conservative, ring-fenced structure typical of quality IPPs; corporate leverage is only C$646M. No obvious balance-sheet stress; C$645M liquidity.
• JV opacity: the EIP 30%-of-France JV introduces a "combined vs. consolidated" reporting duality (EBITDA C$174M consolidated vs C$207M combined) — investors must watch the combined figures; not deceptive but a complexity flag.

Regulatory findings (required sub-section):

• SEC (EDGAR LR + AAER): none possible — Boralex has no CIK and does not file with the SEC. regulatory/regulatory-findings.md (fetched 2026-07-01) confirms total_sec_findings: 0 and the no-CIK limitation.
• Non-SEC enforcement (web): no material FTC/DOJ/FDA/CFPB or Canadian/French regulatory fines, consent decrees, or penalties surfaced.
• Litigation (web): Boralex was the plaintiff and WON the marquee case — the Tribunal de Commerce de Lille ordered Innovent SAS + its president to pay Boralex €50.6M for breach of a wind-development agreement (Innovent appealed). An older O'Leary Funds suit related to a prior Boralex Power takeover mechanic (unitholder-approval threshold) — legacy, immaterial now. No case where Boralex is a defendant in a material adverse action was found.
• Item 3 (Legal Proceedings): Canadian issuer files an Annual Information Form, not a 10-K; the AIF exists on Boralex's site but is not on the shelf (no CIK ingest). Not read web-only — no material litigation disclosed in the coverage reviewed.
• Conclusion: No material regulatory or legal findings against the company — verified via the no-CIK SEC note (LR/AAER inapplicable), web enforcement search, and litigation search as of 2026-07-01. The only "legal" overhang is the deal's own regulatory-approval condition set (Lens 11/13).

---

Phase D — Project & stress-test

Framing: because a fixed-price cash take-out is shareholder- and court-approved, a stand-alone 3-year EPS model is not the operative projection — the payoff is binary (deal closes at C$37.25) or (deal breaks → stock re-rates to fundamentals). Lens 11 therefore models the arb return + break-downside, with a fundamentals sketch for the break scenario. No forecast.ts created (per --watchlist rules).

Lens 11 · Forward Projection (arb math, not EPS path)

Inputs: deal price C$37.25 cash; last price C$36.98; gross spread C$0.27 = ~0.73%; expected close Q4-2026 (~4–5 months from 2026-07-01).

• Base case — deal closes ~Nov-2026: gross +0.73% over ~0.35 yr ≈ ~2.1% annualized `` (Canadian-resident, ignoring FX/tax/borrow). Thin — this is a late-stage, high-probability arb where most of the spread has already collapsed post-vote/court approval. The remaining spread is compensation almost purely for the six outstanding regulatory clearances and time-value.
• Bull (fast close, Q3): spread captured over ~2–3 months → ~3–4% annualized ``. Marginal upside; no bump expected (99.86% vote leaves no room for a topping bid).
• Bear (deal BREAKS on a regulatory block): stock re-rates to stand-alone fundamentals. Pre-bid it sat ~33% below 2021 highs and traded well under the C$37.25 mark; a break likely resets toward the pre-announcement area (~C$28, the ~C$37.25 ÷ 1.318 pre-bid ref) `` → ~−24% from C$36.98. Asymmetry is poor at this price: risking ~24% to make ~0.7%. The trade only makes sense at very high close-confidence and/or bought lower.

Break-scenario fundamentals sketch (only relevant if the deal dies): a small-cap renewable IPP with flat/-EBITDA-to-shareholders under high rates, ~11-yr WACL, C$4.4B debt, and French price drag — i.e., the same profile that de-rated 33%. A rate-cut cycle would help; French tender-price normalization would help; but stand-alone it is a show-me story, which is why the board sold.

No Brier forecast logged (watchlist mode). If one were logged it would be a binary: BLX arrangement closes at C$37.25 by 2026-12-31, p≈0.90 — high, given 99.86% vote + final court order, gated only on standard antitrust/FDI/FERC clearances of a Canadian renewables platform into a Canadian-anchored buyer (low block risk, but France FDI on energy infrastructure is a non-trivial screen).

Lens 12 · Bull vs Bear

Bull (deal-close bull): A shareholder-approved (99.86%), court-approved, all-cash C$37.25 deal from a AAA-credibility infrastructure buyer (Brookfield) with an existing 15% holder (CDPQ) rolling to 30% is about as close to a "sure thing" as public arb gets. Fairness opinions from three banks, both proxy advisors FOR, no financing condition of note (Brookfield/CDPQ balance sheets), and Boralex assets that Brookfield strategically wants (it's expanding its renewable platform). Downside is protected by the asset value itself. Contrarian bull edge: the sector take-private wave (Innergex 2025, Boralex 2026) says private infrastructure capital sees value public markets won't pay for — a read-through bullish for other discounted public IPPs.

Bear (why the stub is a bad risk/reward): ~0.7% to make vs ~24% to lose if it breaks — negatively convex at C$36.98. The break triggers are real: French FDI clearance on energy infrastructure (Paris has grown protective of strategic energy assets and of foreign — incl. Canadian/Brookfield — control), French Competition + Canadian Competition Act + US HSR + FERC + UK FDI — six separate approvals, any of which can slip timing past Q4 or (tail risk) attach remedies. Even a delay erodes the already-thin annualized return. And the underlying business is a rate-sensitive, French-price-exposed small-cap — the break floor is genuinely ~25% lower.

Pre-mortem (18 months out, thesis broke): either (a) a French or EU FDI/competition authority blocked or heavily conditioned the foreign acquisition of a strategic energy platform, the deal terminated, and BLX re-rated to ~C$28 on stand-alone fundamentals in a still-elevated-rate world; or (b) close dragged into 2027 on FDI review, and the annualized arb return collapsed below cash yields — dead money with tail risk.

Are multiples too high? For the acquirer at ~13–14× EBITDA ``, arguably full but defensible for a de-risked contracted platform with a lower cost of capital. For the public stub, "multiple" is now just the C$37.25 clearing price — not a valuation question, a close-probability question.

Contrarian view (what the market refuses to see): the market has priced this as ~90%+ done (0.7% spread). The one under-appreciated tail is French energy-sovereignty politics — France FDI screening of foreign control over its largest independent onshore-wind fleet is the single most plausible source of a remedy/delay, and it is not obviously reflected in a 0.7% spread.

Lens 13 · Devil's Advocate (short-seller)

As a skeptic on owning the arb here:

• The structural break in how it makes money is already conceded — a fixed cash price caps all upside; you cannot "win big," you can only "not lose." That is a terrible payoff to underwrite at a 0.7% spread with 24% downside.
• Regulatory concentration risk: the deal needs French FDI + French Competition + Canadian Competition + US HSR + FERC + UK FDI. France has repeatedly asserted control over strategic energy assets; a Canadian pension (CDPQ) + Brookfield taking 100% of France's #1 independent onshore-wind producer is exactly the kind of transaction a foreign-investment screen exists to scrutinize. Any one remedy or blocking decision breaks the thesis.
• The most dangerous "competitor" is the calendar — every month of FDI review compresses the annualized return; the arb can be "right" on close and still lose to cash yield.
• Underlying-asset weakness if it breaks: negative net income to shareholders on +22% revenue (Q1-26), a −77% Q4 EPS miss, French short-term PPA price erosion, C$4.4B debt, rate sensitivity — the break floor is genuinely low, not a scare number.
• Capital-allocation / incentive angle: CDPQ sits on both sides (15% holder → 30% buyer). The independent process (Special Committee, 3 fairness opinions, 99.86% minority-inclusive vote, ISS/GL FOR) neutralizes the fairness attack — but a short would note the buy-side insider means little chance of a topping bid, capping any speculative upside.
• What single scenario permanently impairs the trade: a French FDI block (plausibility: low-to-moderate; the buyers are institutional and have offered French/local commitments, but energy sovereignty is a live political theme). Plausibility that it delays past Q4: moderate.

Short-seller's bottom line: don't short the deal (99.86% + court approval makes that reckless), but do refuse the long — 0.7%-up / 24%-down is negative expected value unless your close-probability is ≥~97% AND you value the optionality of French-FDI-block tail at ~zero. Better vehicles exist to express "buy discounted renewable IPPs" (the un-bid public peers).

Lens 14 · Management Questions (15, ordered by information value)

1. Which of the six Key Regulatory Approvals (Canadian Competition Act, US HSR, FERC, French FDI, French Competition, UK FDI) remain outstanding as of today, and what is the expected sequencing/timeline for each?
2. Has the French foreign-investment authority (IEF/Ministry of Economy) opened a Phase 2 / conditional review of the acquisition of France's largest independent onshore-wind fleet, and what commitments (local control, jobs, grid) have been offered?
3. What is the Outside Date in the arrangement agreement, and what happens (extension rights, termination) if regulatory approvals are not obtained by then?
4. Is there a break/reverse-termination fee, and under what conditions is it payable — specifically a regulatory-failure termination?
5. Are any regulatory remedies (divestitures, behavioral commitments, FERC mitigation) currently contemplated, and could they alter deal economics or trigger a MAC?
6. What conditions could constitute a Material Adverse Effect allowing the buyers to walk, and how are French power-price declines / a bad quarter carved out?
7. Post-close, how does Brookfield intend to fund the 8.3 GW pipeline and the C$6.8B 2030 CapEx off-balance-sheet — and does the standalone-private structure change the 10–12% IRR floor?
8. How exposed is FY26–27 EBITDA to French short-term/merchant PPA prices, and what is the roll-off schedule of legacy feed-in tariffs into the merchant window?
9. What is the current combined-vs-consolidated EBITDA bridge, and how should the EIP 30%-France JV be modeled going forward?
10. What is the interconnection-queue and permitting status of the top 5 pipeline projects (Tilbury 300 MW, Oxford BESS, Apuiat, Limekiln expansion, NY solar)?
11. What are the turbine and battery-cell supply commitments and price locks for 2026–27 builds, given equipment-cost inflation?
12. What is the WACL today and the concrete path to 14 years by 2030 — which contracts extend and at what prices?
13. How much of the C$4.4B debt reprices or matures in 2026–28, and at what rates versus the in-place cost?
14. If the transaction were not to close, what is the standalone capital plan, dividend policy, and de-leveraging path?
15. What is CDPQ's governance role post-close given it is both a legacy holder and a 30% buyer, and how are minority (now-departed) interests' conflicts documented?

---